{"result": {"id": "66e7b3be-14bd-4c49-91be-e34ab9f38633", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "**Finerenone** is a third-generation, non-steroidal, selective mineralocorticoid receptor antagonist (MRA) with antifibrotic activity. It is characterized by its balanced tissue distribution between the heart and kidneys, which contributes to improved safety in hyperkalemia compared to older MRAs like spironolactone. Finerenone is approved for cardiorenal protection in patients with type 2 diabetes and chronic kidney disease (CKD), specifically for the treatment of diabetic kidney disease. Its unique pharmacological profile makes it a valuable therapeutic option for reducing fibrosis and protecting both cardiac and renal function in this high-risk patient population.", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751559481, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 128, "prompt_tokens": 214, "total_tokens": 342, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 64}, "prompt_cache_hit_tokens": 64, "prompt_cache_miss_tokens": 150}}, "input": {"messages": [{"content": "\nYou are a helpful assistant responsible for generating a comprehensive summary of the data provided below.\nGiven one or two entities, and a list of descriptions, all related to the same entity or group of entities.\nPlease concatenate all of these into a single, comprehensive description. Make sure to include information collected from all the descriptions.\nIf the provided descriptions are contradictory, please resolve the contradictions and provide a single, coherent summary.\nMake sure it is written in third person, and include the entity names so we have the full context.\n\n#######\n-Data-\nEntities: \"FINERENONE\"\nDescription List: [\"A third-generation MRA drug used for diabetic kidney disease\\\"\", \"Finerenone is a non-steroidal MRA with balanced tissue distribution between heart and kidneys, offering better safety in hyperkalemia compared to spironolactone. It is approved for cardiorenal protection in type 2 diabetes with CKD.\", \"Finerenone is a selective mineralocorticoid receptor antagonist with antifibrotic activity\"]\n#######\nOutput:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 500, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_summarize_b1da42a045a6390219e93b0814f5917e4289534edf60a42094183ce4fd215935_v2"}